Diethylthiambutene is an analgesic agent with an effect like that of morphine. Diethylthiambutene mainly used in veterinary. It is highly toxic to cats. Can cause convulsions if injected intravenously. Diethylthiambutene is a synthetic opioid drug. It is under international control according to the UN Single Convention 1961 and its amendments, schedule I.

Fasobegron is an agonist of β3-adrenoreceptor.

Selisistat (EX 527) was discovered by Elixir scientists as a selective human SIRT1 inhibitor and exhibits >200-fold selectivity against SIRT2 and SIRT3. Human SIRT1 is an enzyme that deacetylates the p53 tumor suppressor protein and has been suggested to modulate p53-dependent functions including DNA damage-induced cell death. It was shown that drug was highly safe in toxicology studies. Selisistat passed Phase II clinical trials to treat Huntington’s disease, but that study was discontinued.

Vabicaserin is a 5-hydroxytryptamine 2C (5-HT2C) receptor-selective agonist with an EC50 of 8 nM. Pfizer was developing vabicaserin, an oral serotonin (5-HT)2C receptor agonist, for the treatment of schizophrenia and bipolar disorder. Vabicaserin decreases nucleus accumbens extracellular dopamine levels in rats, without affecting striatal dopamine, indicating mesolimbic selectivity. Vabicaserin had been in phase II clinical trials for the treatment of schizophrenia. However, research of Vabicaserin for the treatment schizophrenia and obesity was discontinued.

Inakalant is diazabicyclo[3.3.1]nonane derivative patented by pharmaceutical company AstraZeneca AB as antiarrhythmic agent.

Barucainide, an IB anti-arrhythmic agent, was evaluated in patients with coronary artery disease. Its antiarrhythmic effect was studied in patients with markedly depressed left-ventricular function. Barucainide was in phase II clinical trials to treat the patients with arrhythmias but the development of the drug was discontinued.

Ruzadolane (previously known as UP 26-91) is a serotonin receptor antagonist that was developed as a non-narcotic, centrally acting analgesic agent for the treatment of anxiety disorder and pain. However, these studies were discontinued.

Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.

Temodox is an antibacterial agent that was studied as a veterinary growth stimulant. Information about the current use of this compound is not available.

Ciadox is Quinoxaline 1,4-dioxide derivative with antimicrobial and promoting activities. Cyadox supplied as premix in the final feed in Eastern Europe and may be used in pigs up to four months of age. Some evidence demonstrated that the mechanism of Ciadox for improving pig growth performance was correlated with several metabolic hormones and growth factors. Cyadox also did not show any adverse effects in carcinogenicity tests with rats and long-term toxicity tests with mice and rats. Cyadox subchronic oral toxicity evaluation shows mild toxicity in non-rodents animals. Metabolic transformation of Ciadox leads to three major metabolites, including 1,4-bisdesoxycyadox, 4-desoxycyadox, and quinoxaline-2-carboxylic acid. Ciadox and metabolites shows virtually no toxic effects in the acute and subchronic oral toxicity study and no mutagenic, carcinogenic activivt.